Betting early on an AI niche, RA Capital seeds a young founder's quest to unlock 'Holy Grail' targets
Artificial intelligence, with its grandiose claims and sweeping promises to revolutionize drug discovery, may seem omnipresent in biopharma now. But Virginia Burger and RA Capital believe there are niches it has yet to touch.
After taking up residency at the star-studded Boston accelerator Petri, Burger’s startup — named New Equilibrium Biosciences — has scored $10 million in seed cash from the VC firm to prove that by reaching into those corners, they could uncover drugs against “Holy Grail” targets in everything from cancer to neurodegenerative diseases.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.